Publications by authors named "Jonathan D Campbell"

Claim this Profile
I
Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA.
Tyler D Wagner, Jacqlyn W Riposo, Kendra M Gould, Jonathan D Campbell, James T Kenney

Pharmacoeconomics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program.
Michael J DiStefano, R Brett McQueen, Hanke Zheng, Harry Gyimah Gyamfi, David Ameyaw, Jonathan D Campbell

Appl Health Econ Health Policy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflation reduction act impact on pharmaceutical investment: insights from investor interviews.
William J Canestaro, Julie A Patterson, Jonathan D Campbell

Health Aff Sch· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State.
Maitreyi Sahu, Tyler D Wagner, Azalea Thomson, Meera Beauchamp, Jonathan D Campbell

JAMA Health Forum· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early impact of the Inflation Reduction Act on small molecule vs biologic post-approval oncology trials.
Hanke Zheng, Julie A Patterson, Jonathan D Campbell

Health Aff Sch· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the Influential Dynamic Inputs in Cost-Effectiveness Analyses.
Melanie D Whittington, Joshua T Cohen, Peter J Neumann, Tyler D Wagner, Jonathan D Campbell

Value Health· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Inflation Reduction Act and Drug Development: Potential Early Signals of Impact on Post-Approval Clinical Trials.
Hanke Zheng, Julie A Patterson, Jonathan D Campbell

Ther Innov Regul Sci· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional Restrictions.
Julia A Rucker, Molly T Beinfeld, Katherine A Clifford, Jonathan D Campbell, James Motyka

Health Aff (Millwood)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges with judging and interpreting a drug's launch price.
Melanie D Whittington, Louis P Garrison, Jonathan D Campbell

Am J Manag Care· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Drug Pricing Patterns Before Loss of Exclusivity.
Ching-Hsuan Lin, Jonathan D Campbell, James Motyka, Joshua T Cohen

Value Health· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act.
Julie A Patterson, James Motyka, Rayan Salih, Robert Nordyke, John M O'Brien, Jonathan D Campbell

Ther Innov Regul Sci· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CMS's Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks.
Julie A Patterson, Tyler D Wagner, Rayan K Salih, Gabri'el D Shabazz, Jonathan D Campbell

Pharmacoecon Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States.
Tyler D Wagner, Lisabeth Buelt, Kimberly Westrich, Jonathan D Campbell

J Comp Eff Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of HIV Screening in Emergency Departments: Results From the Pragmatic Randomized HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial.
Jason Haukoos, Emily Hopkins, Jonathan D Campbell, Michael S Lyons, Richard E Rothman

Ann Emerg Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The accelerated approval program for oncology drugs: celebrating more than 250,000 life-years gained and counting.
Julie Patterson, John Michael O'Brien, Jonathan D Campbell

Am J Manag Care· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medicare Part D Coverage of Drugs Selected for the Drug Price Negotiation Program.
Julie A Patterson, Tyler D Wagner, John M O'Brien, Jonathan D Campbell

JAMA Health Forum· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year.
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson

Pharmacoeconomics· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value.
Avery McKenna, Grace A Lin, Melanie D Whittington, Dmitriy Nikitin, Serina Herron-Smith, Jonathan D Campbell

J Manag Care Spec Pharm· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
Melanie D Whittington, Steven D Pearson, David M Rind, Jonathan D Campbell

Value Health· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
Melanie D Whittington, Jonathan D Campbell, David Rind, Noemi Fluetsch, Grace A Lin

Neurology· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performing Cost-Effectiveness Analyses to Support Policy Making: Key Lessons From the Assessment of Aducanumab.
Jonathan D Campbell, Melanie D Whittington, Steven D Pearson

Neurology· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections.
Monica L Bianchini, Meghan N Jeffres, Jonathan D Campbell

Hosp Pharm· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal for capturing patient experience through extended value frameworks of health technologies.
András Inotai, Ivett Jakab, Diana Brixner, Jonathan D Campbell, Neil Hawkins

J Manag Care Spec Pharm· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of HIV Screening Strategies in the Emergency Department: A Randomized Clinical Trial.
Jason S Haukoos, Michael S Lyons, Richard E Rothman, Douglas A E White, Emily Hopkins, Jonathan D Campbell

JAMA Netw Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient and Payer Preferences for Additional Value Criteria.
Ivett Jakab, Melanie D Whittington, Elizabeth Franklin, Susan Raiola, Jonathan D Campbell

Front Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis